Evidence map›Paper›PMID 31931795›Full record

ArticleRespiratory research2020

Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity.

Lídia Perea, Ana Rodrigo-Troyano, Elisabet Cantó, Marisol Domínguez-Álvarez, Jordi Giner, Ferran Sanchez-Reus, Judit Villar-García, Sara Quero, Marian García-Núñez, Alicia Marín and 5 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Induced sputum: current progress and prospect.European journal of medical research · 2025
    Review
  4. PulmonaryAmerican journal of respiratory and critical care medicine · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Lídia PereaInflammatory Diseases, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
Ana Rodrigo-TroyanoRespiratory Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Autonomous University of Barcelona, Barcelona, Spain.
Elisabet CantóInflammatory Diseases, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
Marisol Domínguez-ÁlvarezPneumology Department, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Autonomous University of Barcelona, Barcelona, Spain.
Jordi GinerRespiratory Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Autonomous University of Barcelona, Barcelona, Spain.
Ferran Sanchez-ReusMicrobiology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Autonomous University of Barcelona, Barcelona, Spain.
Judit Villar-GarcíaDepartment of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.
Sara QueroCentro de Investigación en red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISC III), Barcelona, Spain.
Marian García-NúñezCentro de Investigación en red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISC III), Barcelona, Spain.
Alicia MarínCentro de Investigación en red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISC III), Barcelona, Spain.
Eduard MonsóCentro de Investigación en red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISC III), Barcelona, Spain.
Rosa FanerCentro de Investigación en red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISC III), Barcelona, Spain.
Alvar AgustíCentro de Investigación en red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISC III), Barcelona, Spain.
Silvia VidalInflammatory Diseases, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
Oriol SibilaRespiratory Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Autonomous University of Barcelona, Barcelona, Spain. osibila@santpau.cat.ORCID http://orcid.org/0000-0002-4833-6713
Instituto de Salud Carlos III · ESUniversitat Autònoma de Barcelona · ESHospital de Sant Pau · ESHospital del Mar Research Institute · ES

Funding

Fundació Ramon Pla i Armengol 2015Instituto de Salud Carlos III FIS PI15/00167Instituto de Salud Carlos III FIS PI15/02042Instituto de Salud Carlos III PI18/00311Miguel Servet Research Contract CP16/000039PERIS 2017
6 · The paper itself

Abstract

backgroundFor still unclear reasons, chronic airway infection often occurs in patients with Chronic Obstructive Pulmonary Disease (COPD), particularly in those with more severe airflow limitation. Fatty-acid binding protein 4 (FABP4) is an adipokine involved in the innate immune response against infection produced by alveolar macrophages (Mɸ). We hypothesized that airway levels of FABP4 may be altered in COPD patients with chronic airway infection.

methodsIn this prospective and controlled study we: (1) compared airway FABP4 levels (ELISA) in induced sputum, bronchoalveolar lavage fluid (BALF) and plasma samples in 52 clinically stable COPD patients (65.2 ± 7.9 years, FEV

resultsWe found that: (1) airway levels of FABP4 (but not plasma ones) were reduced in COPD patients vs. controls [219.2 (96.0-319.6) vs. 273.4 (203.1-426.7) (pg/ml)/protein, p = 0.03 in BALF]; (2) COPD patients with airway infection had lower sputum FABP4 levels [0.73 (0.35-15.3) vs. 15.6 (2.0-29.4) ng/ml, p = 0.02]; (3) in COPD patients, the number and proportion of Mɸ were positively related with FABP4 levels in BALF; (4) BALF and sputum FABP4 levels were positively related with FEV

conclusionsAirway FABP4 levels are reduced in COPD patients, especially in those with airway infection and more severe disease. The relationship observed between Mɸ and airway FABP4 levels supports a role for FABP4 in the pathogenesis of airway infection and disease severity in COPD.

Indexed as

Severity of Illness IndexAdultAgedBronchoalveolar Lavage FluidCross-Sectional StudiesFatty Acid-Binding ProteinsFemaleHumansLungMaleMiddle AgedProspective StudiesPulmonary Disease, Chronic ObstructiveRespiratory Function TestsRespiratory Tract InfectionsSputumFABP4 protein, humanFatty Acid-Binding ProteinsBronchoalveolar lavage fluidChronic obstructive pulmonary diseaseFABP4Macrophages

Identifiers

PMID31931795
PMCPMC6958639
OpenAlexW3013461283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.